文献速递自身免疫性与大疱性皮肤病

大疱性和非大疱性类天疱疮早期识别的诊断策略评估

Assessment of Diagnostic Strategy for Early Recognition of Bullous and Nonbullous Variants of Pemphigoid.
PubMed 文献 · JAMA Dermatol · 2019-01-01

该诊断准确性研究分析了1125例疑似类天疱疮患者,评估直接免疫荧光(DIF)、盐裂皮肤间接免疫荧光(IIF SSS)等检测。DIF最敏感(88.3%),IIF SSS特异性高(99.9%)。作者提出包含瘙痒和/或水疱、DIF线状IgG/C3c沉积、IIF SSS表皮侧IgG染色的最小诊断标准,并建议BP180 NC16A酶联免疫吸附试验用于疾病活动度监测。

要点

  • DIF是敏感性最高的诊断试验(88.3%),IIF SSS特异性达99.9%。
  • 作者提出的最小诊断标准包括瘙痒和/或水疱、DIF线状IgG/C3c沉积、IIF SSS表皮侧IgG染色。
  • BP180 NC16A酶联免疫吸附试验对初始诊断无附加价值,推荐作为疾病活动度监测的附加试验。

核心结论

  • 作者认为,诊断大疱性和非大疱性类天疱疮应同时进行DIF和IIF SSS检测,BP180 NC16A酶联免疫吸附试验推荐作为疾病活动度监测的附加试验。

研究设计与样本

  • 配对、多变量诊断准确性研究,纳入2002年1月1日至2015年5月1日期间荷兰格罗宁根水疱性疾病中心连续收治的1125例疑似类天疱疮患者。
  • 纳入标准为具备DIF、IIF SSS和至少1项常规免疫血清学检测的配对数据,样本取自首次诊断时、免疫抑制治疗前,纳入窗口最长4周。
  • 数据分析于2015年10月1日至2017年12月1日进行,结果按2015版诊断准确性报告标准报告。

主要发现

  • 1125例患者中,女性653例(58.0%),男性472例(42.0%),平均(SD)年龄63.2(19.9)岁。
  • 343例诊断为类天疱疮,782例为对照;343例中74例(21.6%,即五分之一)表现为非大疱性类天疱疮。
  • DIF是最敏感的诊断试验(88.3%[n=303];95%CI,84.5%-91.3%),IIF SSS敏感性较低(77.0%[n=263];95%CI,72.2%-81.1%)但特异性高(99.9%;95%CI,99.3%-100%),并补充了大多数DIF阴性病例。
  • 多变量逻辑回归分析显示,BP180 NC16A酶联免疫吸附试验对初始诊断无附加价值。

关键数值与推荐

  • 作者提出的最小诊断标准:(1)瘙痒和/或 predominantly 皮肤水疱;(2)皮肤活检标本DIF显示线状IgG和/或C3c沉积(呈n-锯齿状模式);(3)血清样本IIF SSS显示IgG表皮侧染色阳性;该提案将大疱性类天疱疮扩展至未被识别的非大疱性形式。

临床怎么用

  • 作者认为,诊断大疱性和非大疱性类天疱疮应同时进行DIF和IIF SSS检测。
  • 作者推荐BP180 NC16A酶联免疫吸附试验作为疾病活动度监测的附加试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: A substantial number of patients with bullous pemphigoid do not develop skin blisters and may not have received the correct diagnosis. Diagnostic criteria and an optimal diagnostic strategy are needed for early recognition and trials. OBJECTIVES: To assess the minimal requirements for diagnosis of bullous and nonbullous forms of pemphigoid and to evaluate the optimal diagnostic strategy. DESIGN, SETTING, AND PARTICIPANTS: This paired, multivariable, diagnostic accuracy study analyzed data from 1125 consecutive patients with suspected pemphigoid who were referred to the Groningen Center for Blistering Diseases from secondary and tertiary care hospitals throughout the Netherlands. Eligible participants were patients with paired data on at least (1) a skin biopsy specimen for the direct immunofluorescence (DIF) microscopy test; (2) indirect immunofluorescence on a human salt-split skin substrate (IIF SSS) test; and (3) 1 or more routine immunoserologic tests administered between January 1, 2002, and May 1, 2015. Samples were taken from patients at the time of first diagnosis, before introduction of immunosuppressive therapy, and within an inclusion window of a maximum of 4 weeks. Data analysis was conducted from October 1, 2015, to December 1, 2017. MAIN OUTCOMES AND MEASURES: Pairwise DIF, IIF SSS, IIF on monkey esophagus, BP180 and BP230 enzyme-linked immunosorbent assays, and immunoblot for BP180 and BP230 tests were performed. The results were reported in accordance with 2015 version of the Standards for Reporting Diagnostic Accuracy. RESULTS: Of the 1125 patients analyzed, 653 (58.0%) were women and 472 (42.0%) were men, with a mean (SD) age of 63.2 (19.9) years. In total, 343 participants received a pemphigoid diagnosis, with 782 controls. Of the 343 patients, 74 (21.6%, or 1 in 5) presented with nonbullous pemphigoid. The DIF microscopy was the most sensitive diagnostic test (88.3% [n = 303]; 95% CI, 84.5%-91.3%), whereas IIF SSS was less sensitive (77.0% [n = 263]; 95% CI, 72.2%-81.1%) but was highly specific (99.9%; 95% CI, 99.3%-100%) and complemented most cases with negative DIF findings. Results of the BP180 NC16A enzyme-linked immunosorbent assay did not add diagnostic value for initial diagnosis in multivariable logistic regression analysis of combined tests. These findings lead to the proposed minimal criteria for diagnosing pemphigoid: (1) pruritus and/or predominant cutaneous blisters, (2) linear IgG and/or C3c deposits (in an n-serrated pattern) by DIF on a skin biopsy specimen, and (3) positive epidermal side staining of IgG by IIF SSS on a serum sample; this proposal extends bullous pemphigoid with the unrecognized nonbullous form. CONCLUSIONS AND RELEVANCE: Both DIF and IIF SSS tests should be performed for diagnosis of the bullous and nonbullous variants of pemphigoid, and the BP180 NC16A enzyme-linked immunosorbent assay is recommended as an add-on test for disease activity monitoring.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Meijer JM, Diercks GFH, de Lang EWG, et al. Assessment of Diagnostic Strategy for Early Recognition of Bullous and Nonbullous Variants of Pemphigoid. JAMA Dermatol. 2019. PMID: 30624575. doi:10.1001/jamadermatol.2018.4390

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。